Moody National Bank Trust Division Boosts Stock Position in NeoGenomics, Inc. (NASDAQ:NEO)

Moody National Bank Trust Division raised its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 20.2% during the 4th quarter, HoldingsChannel reports. The firm owned 73,226 shares of the medical research company’s stock after acquiring an additional 12,314 shares during the period. Moody National Bank Trust Division’s holdings in NeoGenomics were worth $1,207,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the stock. Versant Capital Management Inc grew its position in NeoGenomics by 174.9% in the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock valued at $30,000 after buying an additional 1,142 shares during the last quarter. Quarry LP acquired a new stake in shares of NeoGenomics in the 3rd quarter worth $40,000. Blue Trust Inc. boosted its holdings in shares of NeoGenomics by 42.3% in the third quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 987 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of NeoGenomics during the second quarter worth about $57,000. Finally, KBC Group NV raised its holdings in NeoGenomics by 33.1% during the third quarter. KBC Group NV now owns 4,530 shares of the medical research company’s stock worth $67,000 after purchasing an additional 1,127 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

Analyst Upgrades and Downgrades

NEO has been the topic of a number of analyst reports. Benchmark lowered NeoGenomics from a “buy” rating to a “hold” rating in a report on Monday. Bank of America upped their price objective on NeoGenomics from $18.00 to $19.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Needham & Company LLC reissued a “buy” rating and issued a $19.00 target price on shares of NeoGenomics in a report on Friday. Finally, Jefferies Financial Group started coverage on shares of NeoGenomics in a research report on Tuesday, December 10th. They set a “buy” rating and a $22.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.30.

Insider Activity at NeoGenomics

In other NeoGenomics news, General Counsel Alicia C. Olivo sold 5,175 shares of the business’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $15.36, for a total value of $79,488.00. Following the completion of the transaction, the general counsel now directly owns 37,129 shares in the company, valued at approximately $570,301.44. The trade was a 12.23 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 1.30% of the company’s stock.

NeoGenomics Stock Performance

NASDAQ:NEO opened at $12.63 on Tuesday. The company has a current ratio of 1.99, a quick ratio of 1.91 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $1.62 billion, a P/E ratio of -20.70 and a beta of 1.24. The firm has a 50-day moving average price of $16.79 and a two-hundred day moving average price of $15.67. NeoGenomics, Inc. has a twelve month low of $12.13 and a twelve month high of $19.11.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.04. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. The company had revenue of $167.80 million during the quarter, compared to analysts’ expectations of $167.00 million. During the same period in the previous year, the firm posted ($0.06) earnings per share. The business’s revenue for the quarter was up 10.5% compared to the same quarter last year. As a group, research analysts expect that NeoGenomics, Inc. will post -0.16 earnings per share for the current fiscal year.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.